Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC

Colloids and Surfaces B: Biointerfaces

Volumn 81, Issue 2, 2010, Pages 412-421

  Gonzalez Mira, E ^a   Egea, M A ^a   Garcia, M L ^a   Souto, E B ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Draize test; Eytex test; Factorial design; Flurbiprofen; Nanostructured lipid carriers (NLC); Ocular administration; Turbiscan; Ultrasounds

Indexed keywords

DRAIZE TEST; FACTORIAL DESIGN; FLURBIPROFEN; NANOSTRUCTURED LIPID CARRIERS; OCULAR ADMINISTRATION; TURBISCAN; ULTRASOUNDS;

BIOCHEMISTRY; BIOCOMPATIBILITY; DISPERSIONS; LIPOSOMES; NANOPARTICLES; OPTIMIZATION; PHOSPHOLIPIDS; POLYDISPERSITY; STEARIC ACID; SURFACE ACTIVE AGENTS; TESTING; VEGETABLE OILS; ZETA POTENTIAL;

DESIGN;

CASTOR OIL; DODECYL SULFATE; DRUG CARRIER; FLURBIPROFEN; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCEROL STEARATE; IMWITOR; LANOLIN; NANOMATERIAL; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; STEARIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TOLERABILITY; ELECTRICITY; FACTORIAL ANALYSIS; MELTING POINT; NANOENCAPSULATION; NONHUMAN; OPTICAL DENSITY; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; ROOM TEMPERATURE; ZETA POTENTIAL;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASTOR OIL; DRUG CARRIERS; DRUG DESIGN; DRUG STABILITY; DRUG TOLERANCE; EYE; FLURBIPROFEN; IRRITANTS; NANOPARTICLES; PARTICLE SIZE; POLYSORBATES; PREDICTIVE VALUE OF TESTS; RABBITS; SKIN IRRITANCY TESTS; STEARIC ACIDS; SURFACE PROPERTIES; TISSUE ENGINEERING; ULTRASONICS;

EID: 77956650644     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.07.029     Document Type: Article

References (60)

1. Cronau H., Kankanala R.R., Mauger T. Diagnosis and management of red eye in primary care. Am. Fam. Physician 2010, 81:137-144.
2. Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003, 217:89-98.
3. Bielory L., Friedlaender M.H. Allergic conjunctivitis. Immunol. Allergy Clin. North Am. 2008, 28:43-58.
4. Jancevski M., Foster C.S. Cataracts and uveitis. Curr. Opin. Ophthalmol. 2010, 21:10-14.
5. Sunaric-Megevand G., Pournaras C.J. Current approach to postoperative endophthalmitis. Br. J. Ophthalmol. 1997, 81:1006-1015.
6. Almeida D.R., Johnson D., Hollands H., Smallman D., Baxter S., Eng K.T., Kratky V., ten Hove M.W., Sharma S., El-Defrawy S. Effect of prophylactic non-steroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J. Cataract Refr. Surg. 2008, 34:64-69.
7. Sengupta S., Subramoney K., Srinivasan R., Nongrum B., Agarwal V., Pandian D.G., Suchismitha T., Kaliaperumal S. Use of a mydriatic cocktail with a wick for preoperative mydriasis in cataract surgery: a prospective randomised controlled trial. Eye (Lond.) 2010, 24:118-122.
8. Brown J., Hacker H., Schuschereba S.T., Zwick H., Lund D.J., Stuck B.E. Steroidal and non-steroidal antiinflammatory medications can improve photoreceptor survival after laser retinal photocoagulation. Ophthalmology 2007, 114:1876-1883.
9. Korenfeld M.S., Silverstein S.M., Cooke D.L., Vogel R., Crockett R.S. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J. Cataract Refr. Surg. 2009, 35:26-34.
10. Vega E., Egea M.A., Valls O., Espina M., Garcia M.L. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J. Pharm. Sci. 2006, 95:2393-2405.
11. Kim S.J., Flach A.J., Jampol L.M. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv. Ophthalmol. 2010, 55:108-133.
12. Ahuja M., Dhake A.S., Sharma S.K., Majumdar D.K. Topical ocular delivery of NSAIDs. AAPS J. 2008, 10:229-241.
13. Raizman M. Corticosteroid therapy of eye disease. Fifty years later. Arch. Ophthalmol. 1996, 114:1000-1001.
14. Gaynes B.I., Fiscella R. Topical non-steroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002, 25:233-250.
15. Shaikh M.Y., Mars J.S., Heaven C.J. Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. J. Cataract Refr. Surg. 2003, 29:2372-2377.
16. Sawant K.K., Dodiya S.S. Recent advances and patents on solid lipid nanoparticles. Recent Path. Drug Deliv. Formul. 2008, 2:120-135.
17. Shen J., Wang Y., Ping Q., Xiao Y., Huang X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Control. Release 2009, 137:217-223.
18. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol. 2010, 115-141.
19. R.H. Müller, J. Lucks, Arzneistoffträger aus festen Lipidteilchen - Feste Lipid Nanosphären (SLN), European Patent 0605497 (1996).
20. Patil M.N., Gore G.M., Pandit A.B. Ultrasonically controlled particle size distribution of explosives: a safe method. Ultrason. Sonochem 2008, 15:177-187.
21. Patil M.N., Pandit A.B. Cavitation-a novel technique for making stable nano-suspensions. Ultrason. Sonochem. 2007, 14:519-530.
22. Silva R., Little C., Ferreira H., Cavaco-Paulo A. Incorporation of peptides in phospholipid aggregates using ultrasound. Ultrason. Sonochem. 2008, 15:1026-1032.
23. Araujo J., Vega E., Lopes C., Egea M.A., Garcia M.L., Souto E.B. Effect of polymer viscosity on physico-chemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf. B: Biointerfaces 2009, 72:48-56.
24. Abismail B., Canselier J.P., Wilhelm A.M., Delmas H., Gourdon C. Emulsification by ultrasound: drop size distribution and stability. Ultrason. Sonochem. 1999, 6:75-83.
25. Luykx D.M., Peters R.J., van Ruth S.M., Bouwmeester H. A review of analytical methods for the identification and characterization of nano delivery systems in food. J. Agric. Food Chem. 2008, 56:8231-8247.
26. Deshiikan S.R., Papadopoulos K.D. Modified booth equation for the calculation of zeta potential. Colloid Polym. Sci. 1998, 276:117-124.
27. Araujo J., Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B. Optimization and physico-chemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int. J. Pharm. 2010, 393:167-175.
28. Westesen K., Bunjes H., Koch M.H.J. Physico-chemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release 1997, 48:223-236.
29. Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J. Control. Release 2009, 136:2-13.
30. Gordon V.C. Utilization of biomacromolecular in vitro assay systems in the prediction of in vivo toxic responses. Lens Eye Toxic. Res. 1992, 9:211-227.
31. Soto R.J., Gordon V.C. An in vitro method for estimating ocular irritation. Toxicol. Vitro 1990, 4:332-335.
32. Fielder R.J. Acceptance of in vitro studies by regulatory authorities. Toxicol. Vitro 1994, 8:911-916.
33. Duprat P., Delsaut L., Gradiski D. Irritant power of the principle chlorinated aliphatic solvents on the skin and ocular mucosa of the rabbit. Eur. J. Toxicol. Environ. Hyg. 1976, 9:171-177.
34. Kay J.H., Calandra J.C. Interpretation of eye irritation tests. J. Soc. Cosmet. Chem. 1962, 13:281-289.
35. Passantino A. Application of the 3Rs principles for animals used for experiments at the beginning of the 21st century. Ann. Rev. Biomed. Sci. 2008, 10:27-32.
36. Araujo J., Gonzalez E., Egea M.A., Garcia M.L., Souto E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009, 5:394-401.
37. Jenning V., Thunemann A.F., Gohla S.H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000, 199:167-177.
38. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
39. Shah M., Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full factorial design. AAPS Pharm. Sci. Tech. 2010, 11:489-496.
40. Singh S., Dobhal A.K., Jain A., Pandit J.K., Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: zidovudine. Chem. Pharm. Bull. (Tokyo) 2010, 58:650-655.
41. Varshosaz J., Ghaffari S., Khoshayand M.R., Atyabi F., Azarmi S., Kobarfard F. Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J. Liposome Res. 2010, 20:97-104.
42. Zimmer A., Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Deliv. Rev. 1995, 8:61-73.
43. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B: Biointerfaces 2005, 45:167-173.
44. Jia L.J., Zhang D.R., Li Z.Y., Feng F.F., Wang Y.C., Dai W.T., Duan C.X., Zhang Q. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv. 2009.
45. Asasutjarit R., Lorenzen S.I., Sirivichayakul S., Ruxrungtham K., Ruktanonchai U., Ritthidej G.C. Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection. Pharm. Res. 2007, 24:1098-1107.
46. Finney J.L The Structural Basis of the Hydrophobic Interaction. Hydration Process in Biology 1999, IOS Press, pp. 115-124.
47. Bhaskar K., Anbu J., Ravichandiran V., Venkateswarlu V., Rao Y.M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009, 8:6.
48. Bogataj M, Vovk T., Kerec M., Dimnik A., Grabnar I., Mrhar A. The correlation between zeta potential and mucoadhesion strength on pig vesical mucosa. Biol. Pharm. Bull. 2003, 26:743-746.
49. Souto E.B., Wissing S.A., Barbosa C.M., Muller R.H. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur. J. Pharm. Biopharm. 2004, 58:83-90.
50. Li X., Nie S.F., Kong J., Li N., Ju C.Y., Pan W.S. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm. 2008, 363:177-182.
51. Bunjes H., Westesen K., Koch M.H.J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 1996, 129:159-173.
52. Saupe A., Wissing S.A., Lenk A., Schmidt C., Muller R.H. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)-structural investigations on two different carrier systems. Biomed. Mater. Eng. 2005, 15:393-402.
53. Doktorovova S., Araujo J., Garcia M.L., Rakovsky E., Souto E.B. Formulating fluticasone propionate in novel PEG containing nanostructured lipid carriers (PEGNLC). Colloids Surf. B: Biointerfaces 2010, 75:538-542.
54. Jenning V., Lippacher A., Gohla S.H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J. Microencapsul. 2002, 19:1-10.
55. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24:4283-4300.
56. Radomska-Soukharev A., Muller R.H. Chemical stability of lipid excipients in SLN-production of test formulations, characterisation and short-term stability. Pharmazie 2006, 61:425-430.
57. Joshi M.D, Muller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161-172.
58. Jiao J. Polyoxyethylated non-ionic surfactants and their applications in topical ocular drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1663-1673.
59. Schoenwald R.D., Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J. Pharm. Sci. 1980, 69:391-394.
60. Escribano E., Calpena A.C., Queralt J., Obach R., Domenech J. Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula. Eur. J. Pharm. Sci. 2003, 19:203-210.